|
2024 Conference Publication Baseline characteristics and molecular testing of Australian patients with IDH1 mutated cholangiocarcinoma: initial results from the phase IIIb ProvIDHe studySim, H-W., McLachlan, S-A., Dean, A., Price, T.J., Eastgate, M., Rimassa, L., Mercade, T. Macarulla, Malka, D., Gharbi, H., Robert, R., Sullivan, A. and Vogel, A. (2024). Baseline characteristics and molecular testing of Australian patients with IDH1 mutated cholangiocarcinoma: initial results from the phase IIIb ProvIDHe study. ESMO Asia Congress 2024, Singapore, 6 – 8 December 2024. Amsterdam, Netherlands: Elsevier. doi: 10.1016/j.annonc.2024.10.171 |
|
2024 Conference Publication Routine, prospective DPYD genotyping guided dose-individualisation for patients receiving fluoropyrimidines: Implementation, prevalence and patient safety outcomes from a multi-institutional clinical trialNalder, Mark, Kulasegaran, Tivya, Lundie, Ben, Woods, Rick, Eastgate, Melissa A., Wyld, David and Burge, Matthew E. (2024). Routine, prospective DPYD genotyping guided dose-individualisation for patients receiving fluoropyrimidines: Implementation, prevalence and patient safety outcomes from a multi-institutional clinical trial. 2024 ASCO Annual Meeting, Chicago, IL, United States, 31 May–4 June 2024. Alexandria, VA, United States: American Society of Clinical Oncology. doi: 10.1200/JCO.2024.42.16_suppl.12121 |
|
2023 Conference Publication CHARLI: A phase Ib/II trial of ipilimumab-nivolumab-denosumab or nivolumab-denosumab in patients with unresectable stage III and IV melanomaLau, Peter Kar Han, Harris, Samuel John, Eastgate, Melissa A., Kee, Damien, Mant, Andrew, Nott, Louise M., Gedye, Craig, Inderjeeth, Andrisha Jade, Underhill, Craig, Weppler, Alison Margaret, Wallace, Roslyn, Lee, Belinda, Au-Yeung, George, Williams, Narelle, Ariza Ospino, Daniel, Gonzales, Louise, Shackleton, Mark J., Lo, Serigne N., McArthur, Grant A. and Sandhu, Shahneen (2023). CHARLI: A phase Ib/II trial of ipilimumab-nivolumab-denosumab or nivolumab-denosumab in patients with unresectable stage III and IV melanoma. 2023 ASCO Annual Meeting, Chicago, IL United States, 2-6 June 2023. Alexandria, VA United States: American Society of Clinical Oncology. doi: 10.1200/jco.2023.41.16_suppl.9525 |
|
2023 Conference Publication Chemoradiotherapy with concurrent durvalumab for the palliative treatment of oligometastatic esophageal and gastroesophageal carcinoma with dysphagia: A single arm phase 2 clinical trial, PALEODay, Fiona, Sridharan, Swetha, Michael, Michael, Christophersen, Louise, Moore, Melissa M., Eastgate, Melissa A., Thompson, Stephen, MWEEMPWA, ANGELA, Oldmeadow, Christopher, Fraser, Allison and Martin, Jarad (2023). Chemoradiotherapy with concurrent durvalumab for the palliative treatment of oligometastatic esophageal and gastroesophageal carcinoma with dysphagia: A single arm phase 2 clinical trial, PALEO. 2023 ASCO Annual Meeting, Chicago, IL United States, 2-6 June 2023. Alexandria, VA United States: American Society of Clinical Oncology. doi: 10.1200/jco.2023.41.16_suppl.tps4172 |
|
2022 Conference Publication Adjuvant therapy in resected melanoma: Experience from royal brisbane and women's hospitalTurner, Cassie L. and Eastgate, Melissa (2022). Adjuvant therapy in resected melanoma: Experience from royal brisbane and women's hospital. HOBOKEN: WILEY. |
|
2022 Conference Publication A multicenter, randomized, double-blind phase III study of HBI-8000 combined with nivolumab versus placebo with nivolumab in patients with unresectable or metastatic melanoma not previously treated with PD-1 or PD-L1 inhibitorsKhushalani, N.I., Shue, H., Gedye, C., Mazumder, A., Sharma, S., Eastgate, M., Majem Tarruella, M., Antonanzas Basa, M., Montaudie, H., Marais-Nieman, R., de la Cruz Merino, L., Clements, A., Mortier, L., Jameson, M., Shojaei, F., Ning, J., Aiyer, L., Gillings, M., Kabbinavar, F. and Ascierto, P. (2022). A multicenter, randomized, double-blind phase III study of HBI-8000 combined with nivolumab versus placebo with nivolumab in patients with unresectable or metastatic melanoma not previously treated with PD-1 or PD-L1 inhibitors. ESMO Asia Congress 2022, Singapore, 2-4 December 2022. Amsterdam, Netherlands: Elsevier. doi: 10.1016/j.annonc.2022.10.052 |
|
2022 Conference Publication Cost-benefit of pre-treatment dihydropyrimidine dehydrogenase genotyping to individualise fluoropyrimidine-based chemotherapy in a contemporary Australian settingKim, Hansoo, Kulasegaran, Tivya, Eastgate, Melissa, Wyld, David, Burge, Matthew and Nalder, Mark (2022). Cost-benefit of pre-treatment dihydropyrimidine dehydrogenase genotyping to individualise fluoropyrimidine-based chemotherapy in a contemporary Australian setting. HOBOKEN: WILEY. |
|
2022 Conference Publication Tumour naive circulating tumour DNA (ctDNA) analysis in patients (pts) with resected colorectal cancer (CRC) in the phase III ASCOLT trialDay, D., Starus, A., Lamik, A., Sieber, O., Begbie, S., Bonaventura, A., Rai, S., Karanth, N., Underhill, C. R., Nott, L. M., Van Hazel, G., Van Hagen, T., Wong, M., Saqib, A., Eastgate, M., Srivastav, R., Chia, J., Toh, H. C., Jones, F. and Segelov, E. (2022). Tumour naive circulating tumour DNA (ctDNA) analysis in patients (pts) with resected colorectal cancer (CRC) in the phase III ASCOLT trial. Annual Meeting of the European-Society-for-Medical-Oncology (ESMO), Electr Network, Sep 09-13, 2022. AMSTERDAM: ELSEVIER. doi: 10.1016/j.annonc.2022.07.518 |
|
2022 Conference Publication Toxicity and response to ipilimumab and nivolumab in elderly patients with metastatic melanoma: A multicenter retrospective analysisPathmanathan, Shivanshan, Babu, Hari S., Dzienis, Marcin Radoslaw, Azer, Mary and Eastgate, Melissa A. (2022). Toxicity and response to ipilimumab and nivolumab in elderly patients with metastatic melanoma: A multicenter retrospective analysis. Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Electr Network, Jun 03-07, 2022. PHILADELPHIA: LIPPINCOTT WILLIAMS & WILKINS. |
|
2019 Conference Publication Resistance to immunotherapy is associated with high parenchymal PD1+CD8+/CD8+T cells (PD1tR) driven by tumour CD155de Oliveira, A. Lepletier, Madore, J., O'donnell, S., Johnston, R. L., Eastgate, M., Mallardo, D., Ascierto, P. A., Massi, D., Merelli, B., Mandala, M., Wilmott, J. S., Bald, T., Stagg, J., Routy, B., Long, G. V., Scolyer, R. A., Waddell, N., Dougall, W. C., Teng, M. W. L. and Smyth, M. (2019). Resistance to immunotherapy is associated with high parenchymal PD1+CD8+/CD8+T cells (PD1tR) driven by tumour CD155. Immuno-Oncology Congress of the European-Society-for-Medical-Oncology (ESMO), Geneva, Switzerland, 11-14 December 2019. Oxford, United Kingdom: Oxford University Press. |
|
2019 Conference Publication Royal Brisbane MedicalOncology Clinic Activity ReviewKuchel, Anna, Kermond, Anna, Lonton, Jennifer, Wyld, David and Eastgate, Melissa (2019). Royal Brisbane MedicalOncology Clinic Activity Review. COSA's 46th Annual Scientific Meeting, Urological cancer; Age and gender in cancer practice; Digital health in cancer, Adelaide, SA Australia, 12–14 November 2019. Chichester, West Sussex United Kingdom: Wiley-Blackwell. |
|
2018 Conference Publication Colorectal cancer patient reported outcomes: putting theory into practiceBryant, Geoffrey, Eastgate, Melissa, Wyld, David, Burge, Matthew, Thaker, Darshit and Busato, Matthew (2018). Colorectal cancer patient reported outcomes: putting theory into practice. COSA's 45th Annual Scientific Meeting, Mesothelioma and Gastro‐Intestinal Cancers: Technology and Genomics, Perth Convention and Exhibition Centre, 13–15 November 2018. Chichester, West Sussex, United Kingdom: Wiley-Blackwell. |
|
2018 Conference Publication Dietary patterns and attitudes in cancer survivorsLee, Shu Fen , Wyld, David , Eastgate, Melissa and Brown, Teresa (2018). Dietary patterns and attitudes in cancer survivors. Victorian Cancer Survivorship Conference, Melbourne, Australia, 8-9 February 2018. |
|
2017 Conference Publication Outcomes comparing right and left-sided metastatic colorectal cancer: A multi-centre retrospective analysis in Queensland, AustraliaAllen, Michael , Conroy, Sophie , Eastgate, Melissa , Wyld, David, Whitehall, Vicki and Burge, Matthew (2017). Outcomes comparing right and left-sided metastatic colorectal cancer: A multi-centre retrospective analysis in Queensland, Australia. Australasian Gastro-Intestinal Trials Group (AGITG) 2017 Annual Scientific Meeting, Cairns Convention Centre, Cairns, Australia, 4-6 October 2017. AGITG. |
|
2017 Conference Publication Exploring attitudes and barriers to research in medical oncology trainingLadwa, R. and Eastgate, M. (2017). Exploring attitudes and barriers to research in medical oncology training. Medical Oncology Group of Australia Incorporated Annual Scientific Meeting, Real World Oncology: Translating Discovery in to Practice, Pullman Hotel, Albert Park, Melbourne, VIC, 2-4 August 2017. Chichester, West Sussex United Kingdom: Wiley-Blackwell Publishing. doi: 10.1111/ajco.12729 |
|
2017 Conference Publication Single institution review of the correlation between the clinical and histopathological staging in newly diagnosed rectal cancer patients in 2015Thanayankeezhil, Padmini, Wyld, David, Burge, Matthew and Eastgate, Melissa (2017). Single institution review of the correlation between the clinical and histopathological staging in newly diagnosed rectal cancer patients in 2015. Australasian Gastro-Intestinal Trials Group (AGITG) 2017 Annual Scientific Meeting, Cairns Convention Centre, Cairns, Australia, 4-6 October 2017. AGITG. |
|
2017 Conference Publication Catheter-Associated Bloodstream Infections (CA-BSI) in Adults with Cancer: A Prospective Randomized Controlled TrialMollee, Peter, Okano, Satomi, Looke, David, Kennedy, Glen, Harper, John, Clouston, John, Van Kuilenburg, Rosita, Geary, Alanna, Joubert, Warren, Eastgate, Melissa and Jones, Mark (2017). Catheter-Associated Bloodstream Infections (CA-BSI) in Adults with Cancer: A Prospective Randomized Controlled Trial. In: 59th Annual Meeting of the American-Society-of-Hematology (ASH), Atlanta, GA United States, (). 9-12 December 2017. |
|
2017 Conference Publication Characterising Acute Ward Admissions of Advanced Cancer Patients to the Royal Brisbane HospitalMittal, Dolly, Eustace, Matthew, Eastgate, Melissa, Burge, Matthew and Wyld, David (2017). Characterising Acute Ward Admissions of Advanced Cancer Patients to the Royal Brisbane Hospital. WILEY. |
|
2014 Conference Publication Pathologic response of rectal adenocarcinoma to preoperative long course chemoradiotherapy (Lccrt). An assessment at a tertiary referral hospitalChristie, Hayden, Burge, Matthew, Eastgate, Melissa and Wyld, David (2014). Pathologic response of rectal adenocarcinoma to preoperative long course chemoradiotherapy (Lccrt). An assessment at a tertiary referral hospital. COSA's 41st Annual Scientific Meeting. Joining Forces - Accelerating Progress, Melbourne, Australia, 2-4 December, 2014. Chichester, West Sussex, United Kingdom: Wiley-Blackwell Publishing. doi: 10.1111/ajco.12305 |
|
2014 Conference Publication Assessment of time to commencement of neoadjuvant long course chemoradiotherapy (Lccrt) for locally advanced rectal adenocarcinoma patients in a tertiary referral hospitalChristie, Hayden, Burge, Matthew, Eastgate, Melissa and Wyld, David (2014). Assessment of time to commencement of neoadjuvant long course chemoradiotherapy (Lccrt) for locally advanced rectal adenocarcinoma patients in a tertiary referral hospital. COSA's 41st Annual Scientific Meeting. Joining Forces - Accelerating Progress, Melbourne, Australia, 2-4 December, 2014. Chichester, West Sussex, United Kingdom: Wiley-Blackwell Publishing. doi: 10.1111/ajco.12305 |
